These facts come from FDA’s list of registered outsourcing facilities, updated November 17, 2026, and from the inspection report FDA posted with it.1 None of the 164 FDA warning letters about GLP-1 drugs in our database names this company.
What does FDA’s record show, in brief?
| Facility | Vitae Enim Vitae Scientific, Inc. |
| Location | San Diego, California |
| Type | 503B outsourcing facility |
| Registered since | January 2, 2024 |
| Latest registration | December 29, 2025 |
| Last FDA inspection | Not yet inspected |
| Inspection dates | — |
| Form 483 | Not issued |
| FDA action after the inspection | None listed |
| Compounds sterile drugs from bulk | No |
| FDA warning letters on GLP-1 drugs | 0 |
Has this facility recalled any drugs?
FDA’s enforcement reports list 4 recalled products from this facility, from March 14, 2022 to March 14, 2022: 4 in Class II. None of them names a GLP-1 drug. Class I is the most serious: FDA uses it when the product could cause serious harm.3
| Started | Class | Product | Reason |
|---|---|---|---|
| 2022-03-14 | II | TETRACAINE 1% Tetracaine HCI Injection | Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the … |
| 2022-03-14 | II | PHENOBARBITAL Sodium Injection | Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the … |
| 2022-03-14 | II | PHENOBARBITAL Sodium Injection | Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the … |
| 2022-03-14 | II | PAPAVERINE HYDROCHLORIDE Injection | Lack of Assurance of Sterility: deviations from Current Good Manufacturing Practices (CGMP) that call into question the … |
Is the pharmacy behind my prescription on FDA’s list?
Type a pharmacy name or city. The search runs over all 100 facilities on FDA’s list; a 503A pharmacy that compounds for individual prescriptions is licensed by its state and is not on this list.
Where are the registered outsourcing facilities?
8 of the 100 facilities on FDA’s list are in California. The chart counts them by state; choose a view to see which ones FDA has inspected.
Which other facilities are in the same state?
What does it mean that a pharmacy is a 503B outsourcing facility?
An outsourcing facility is a compounder that has chosen to register with FDA under section 503B of the Federal Food, Drug, and Cosmetic Act. It must re-register every year between October 1 and December 31 and pay an annual fee; a facility that does not is removed from FDA’s list on January 1.1 Once registered, it joins the list of facilities FDA plans to inspect on a risk-based schedule.1
A Form FDA 483 lists what investigators observed during an inspection. FDA states that a 483 is issued when investigators see significant objectionable conditions, and that it is not a final agency determination that the law was broken.1 Registration is not FDA approval of the drugs a facility makes: compounded drugs are not FDA-approved.
Sources
- FDA. Facilities registered as human drug compounding outsourcing facilities under section 503B, updated November 17, 2026, with its notes on registration and inspections. fda.gov
- FDA. Registered outsourcing facilities: inspection status of Vitae Enim Vitae Scientific, Inc.. fda.gov
- FDA. Drug recall enforcement reports for Vitae Enim Vitae Scientific, Inc., read through openFDA on November 20, 2026. open.fda.gov
Log every dose in mg with the vial it came from, so there is a record if something goes wrong.
Open Dose Insider